Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Closed - Nasdaq Stockholm 14:59:43 03/11/2023 +03			5-day change	1st Jan Change
0.1604 ^SEK	-1.11%		-.--%	-

28/06/25	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/06/24	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Market Cap	182M 18.59M 16.11M 15.23M 13.79M 25.88M 1.78B 26.07M 69.92M 904M 69.84M 68.3M 2.88B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 40.47M 35.05M 33.14M 30.01M 56.32M 3.88B 56.74M 152M 1.97B 152M 149M 6.28B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

28/06/25	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/06/24	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03/11/23	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23/10/23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
20/10/23	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
20/10/23	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
20/10/23	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
16/10/23	Irras Obtains Extension for SEK20 Million Loan	MT
16/10/23	Irras extends SEK 20 million short-term loan	FW
02/10/23	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
19/09/23	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
22/05/23	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
22/05/23	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
20/02/23	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

IRRS ABNPV Stock

Stocks

IRRAS

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRS ABNPV

Latest news: IRRS ABNPV

Analysts' recommendations: IRRS ABNPV

Press Releases: IRRS ABNPV

Quotes and Performance

Price Extremes

Managers and Directors: IRRS ABNPV

Medical Devices & Implants

Financials

Company Profile

20/10/23	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
20/10/23	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
20/10/23	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
16/10/23	IRRAS publishes prospectus	AQ
15/10/23	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	01/07/2021
Griffen Stapp DFI	Director of Finance/CFO	40	17/06/2021
Sten Gustafsson IRC	Investor Relations Contact	-	09/03/2021

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	01/06/2015
Marios Fotiadis CHM	Chairman	53	18/08/2020
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	01/09/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRS ABNPV	-1.11%	-.--%	-.--%	-9.43%	16.9M
STRYKER CORPORATION	-0.13%	+1.83%	-25.35%	-3.85%	108B
SMITH & NEPHEW PLC	-1.05%	+1.12%	-25.09%	-2.54%	11.89B
GLAUKOS CORPORATION	+0.34%	-7.22%	+112.90%	+128.54%	10.09B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-0.11%	-5.11%	-54.48%	-71.65%	3.97B
DOUBLE MEDICAL TECHNOLOGY INC.	-0.20%	-4.44%	-28.37%	+23.21%	2.36B
INSPIRE MEDICAL SYSTEMS, INC.	+0.38%	+20.05%	-7.60%	-64.63%	2.15B
INSIGHT LIFETECH CO., LTD.	-0.88%	-5.48%	-	-	1.84B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+0.07%	-4.17%	-22.83%	-30.97%	1.5B
Average	-0.30%	+0.41%	-6.35%	-3.91%	15.77B
Weighted average by Cap.	-0.17%	+1.09%	-15.95%	+3.11%

	2023	2024
Net sales	42.88M 4.39M 3.8M 3.59M 3.25M 6.11M 421M 6.15M 16.5M 213M 16.48M 16.11M 680M	57.98M 5.93M 5.14M 4.86M 4.4M 8.26M 569M 8.32M 22.31M 289M 22.28M 21.79M 920M
Net income	-209M -21.37M -18.51M -17.5M -15.85M -29.74M -2.05B -29.96M -80.36M -1.04B -80.27M -78.49M -3.31B	-95.98M -9.82M -8.51M -8.04M -7.28M -13.67M -942M -13.77M -36.93M -478M -36.89M -36.07M -1.52B
Net Debt	43.85M 4.49M 3.89M 3.67M 3.33M 6.24M 430M 6.29M 16.87M 218M 16.85M 16.48M 696M	214M 21.87M 18.95M 17.91M 16.22M 30.44M 2.1B 30.67M 82.25M 1.06B 82.16M 80.34M 3.39B

3 years	0.16	0.18
5 years	0.11	5.09
10 years	0.11	47